LEWIS, STEVEN L. MD, FAAN
Silvestri, Nicholas J. MD, FAAN
doi : 10.1212/CON.0000000000001150
Muscle weakness is a common feature of many neuromuscular disorders. This article outlines a symptoms and signs approach to the patient presenting with neuromuscular weakness, highlighting key aspects of the clinical history and examination.
Raja, Shruti M. MD
doi : 10.1212/CON.0000000000001205
This article reviews the pathophysiology, epidemiology, clinical features, diagnosis, and treatment of Lambert-Eaton myasthenic syndrome (LEMS) and botulism, presynaptic disorders of neuromuscular transmission in which rapid diagnosis improves long-term outcomes.
Hehir, Michael K. II MD; Li, Yuebing MD, PhD, FAAN
doi : 10.1212/CON.0000000000001161
This article reviews updated diagnostic procedures and currently available treatment modalities for myasthenia gravis (MG).
Manousakis, Georgios MD, FAAN
doi : 10.1212/CON.0000000000001179
This article outlines the salient clinical, serologic, electrophysiologic, imaging, and histopathologic findings and treatment options for the idiopathic inflammatory myopathies, including those related to immune checkpoint inhibitors and SARS-CoV-2.
Goyal, Namita A. MD, FAAN
doi : 10.1212/CON.0000000000001204
This article highlights the clinical and diagnostic features of inclusion body myositis (IBM) and provides recent insights into the pathomechanisms and therapeutic strategies of the disease.
Lee, Bo Hoon MD
doi : 10.1212/CON.0000000000001208
This article reviews the history, epidemiology, genetics, clinical presentation, multidisciplinary management, and established and emerging therapies for the dystrophinopathies.
Johnson, Nicholas E. MD, FAAN; Statland, Jeffrey M. MD
doi : 10.1212/CON.0000000000001178
The limb-girdle muscular dystrophies (LGMDs) are a group of inherited muscle disorders with a common feature of limb-girdle pattern of weakness, caused by over 29 individual genes.
Hamel, Johanna I. MD
doi : 10.1212/CON.0000000000001184
Myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2) are genetic disorders affecting skeletal and smooth muscle, heart, brain, eyes, and other organs.
Mul, Karlien MD, PhD
doi : 10.1212/CON.0000000000001155
This article reviews the current knowledge on the clinical characteristics and disease mechanism of facioscapulohumeral muscular dystrophy (FSHD), as well as advances in targeted therapy development.
Tarnopolsky, Mark A. MD, PhD, FRCP
doi : 10.1212/CON.0000000000001182
Metabolic myopathies are disorders that affect skeletal muscle substrate oxidation. Although some drugs and hormones can affect metabolism in skeletal muscle, this review will focus on the genetic metabolic myopathies.
Trivedi, Jaya R. MD, FAAN
doi : 10.1212/CON.0000000000001183
This article describes the clinical features, diagnosis, pathophysiology, and management of nondystrophic myotonia and periodic paralysis.
Findlay, Andrew R. MD; Weihl, Conrad C. MD, PhD
doi : 10.1212/CON.0000000000001203
This article discusses the foundational concepts of genetic treatment strategies employed in neuromuscular medicine, as well as the importance of genetic testing as a requirement for applying gene-based therapy.
Reoma, Lauren B. MD, FAAN; Nath, Avindra MD, MBBS, FAAN; Griggs, Robert C. MD, FAAN
doi : 10.1212/CON.0000000000001240
The discipline of experimental neurotherapeutics targets the process and operation of translating scientific discoveries into new treatments for neurologic diseases and has been instrumental in the progression of many areas of neurology.
Owens, James W. M. Jr MD, PhD; Zazulia, Allyson R. MD
Owens, James W. M. Jr MD, PhD; Zazulia, Allyson R. MD
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟